Stock AEON AEON BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights AEON Biopharma, Inc.

Equities

AEON

US00791X1000

Market Closed - Nyse
Other stock markets
 16:00:00 2024-06-07 EDT 		5-day change 1st Jan Change
1.68 USD +2.44% Intraday chart for AEON Biopharma, Inc. +6.33% -76.67%
05-16 AEON Biopharma, Inc. Announces Termination of Peter Reynolds as Chief Financial Officer, Effective May 17, 2024 CI
05-16 AEON Biopharma, Inc. Announces Executive Changes CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine
CI
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
AEON Biopharma, Inc. Provides Update on Development Pipeline
CI
US Equity Markets Close Higher Friday Following Weak Jobs Report
MT
Sector Update: Health Care Stocks Mixed Late Afternoon
MT
Sector Update: Health Care
MT
Top Midday Decliners
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
MT
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial
MT
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
CI
Sector Update: Health Care Stocks Slide Late Afternoon
MT
Sector Update: Health Care
MT
AEON Biopharma Shares Tumble on Wider Q4 Loss
MT
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
AEON Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
AEON Biopharma, Inc. Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
CI
AEON Biopharma, Inc. Presents Positive Clinical and Pre-Clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, At TOXINS 2024
CI
AEON Biopharma, Inc. Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
CI
AEON Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
AEON Biopharma, Inc. Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AEON Stock
  4. News AEON Biopharma, Inc.
  5. Highlights